Supplier
Lee Memorial Health System
Lee Memorial Health System was paid $97.77M by Medicaid between Jan 2018 and Dec 2024, across 594 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoLEE MEMORIAL HEALTH SYSTEM
FT MYERS, FL 33901
FT MYERS, FL 33901
33aNPI1558302570assigned 06/09/2006
33bProvider typeSpecialty Pharmacy
28Total paid$97.77M
24GClaims2,344,912
24DCodes billed594
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialty Pharmacy providers in Florida
Rank by total paid#1 of 11
Median peer was paid$297.62
This provider vs. median328,509×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SPENCE, BENJAMIN controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 96,413 | $1.71M | |
| 2019 | 426,771 | $18.66M | |
| 2020 | 395,050 | $14.15M | |
| 2021 | 534,232 | $19.83M | |
| 2022 | 538,055 | $22.14M | |
| 2023 | 236,417 | $12.58M | |
| 2024incomplete | 117,974 | $8.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 106,751 | 97,370 | $10.51M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.2% | 77,488 | 72,409 | $9.04M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8.8% | 77,250 | 23,724 | $8.64M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.2% | 81,545 | 61,408 | $6.07M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.2% | 69,789 | 22,691 | $5.13M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.1% | 48,158 | 17,188 | $4.03M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.1% | 34,560 | 30,204 | $2.99M |
| J7030 | Infusion, normal saline solution , 1000 cc | 2.2% | 18,222 | 12,055 | $2.12M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 18,468 | 10,202 | $2.03M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 16,838 | 16,036 | $1.62M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.6% | 17,251 | 14,026 | $1.60M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 15,382 | 14,954 | $1.40M |
582 more codes
| 99285 | Emergency room visit (most serious) | 1.3% | 11,426 | $1.31M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 8,932 | $1.29M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.2% | 2,759 | $1.21M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 11,014 | $1.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 34,487 | $1.14M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 6,467 | $1.05M |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.0% | 13,528 | $993K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,731 | $884K |
| 80053 | Comprehensive metabolic panel | <1% | 93,703 | $725K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,500 | $714K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 608 | $709K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,329 | $698K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 1,514 | $697K |
| 97161 | <1% | 5,347 | $682K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 8,910 | $634K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,790 | $601K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,455 | $568K |
| 87088 | <1% | 35,175 | $542K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,656 | $522K |
| G0378 | Hospital observation service, per hour | <1% | 24,192 | $514K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,958 | $510K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 3,445 | $507K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,776 | $497K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 32,659 | $486K |
| 95782 | <1% | 940 | $455K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 26,622 | $431K |
| 97602 | <1% | 5,696 | $424K | |
| 92523 | <1% | 3,317 | $420K | |
| 29581 | <1% | 5,471 | $414K | |
| 93325 | <1% | 4,325 | $413K | |
| 92579 | <1% | 4,161 | $393K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,359 | $391K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,690 | $391K |
| 97165 | <1% | 2,684 | $356K | |
| 44970 | <1% | 187 | $352K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,231 | $348K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 14,442 | $348K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,914 | $347K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13,046 | $324K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,412 | $321K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 5,427 | $321K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,240 | $317K |
| 95816 | <1% | 2,031 | $315K | |
| 74018 | <1% | 17,152 | $301K | |
| 92557 | <1% | 2,364 | $274K | |
| 86850 | <1% | 8,787 | $268K | |
| 97162 | <1% | 4,254 | $257K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,554 | $255K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 94,344 | $251K |
| 59025 | Fetal non-stress test | <1% | 10,140 | $248K |
| 54161 | <1% | 370 | $240K | |
| 87807 | <1% | 3,613 | $238K | |
| 92526 | <1% | 5,801 | $237K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,141 | $232K |
| 93320 | <1% | 1,050 | $217K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,500 | $215K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,708 | $214K |
| 97166 | <1% | 2,203 | $206K | |
| 82962 | <1% | 19,882 | $202K | |
| 81001 | <1% | 53,790 | $199K | |
| 81003 | <1% | 15,435 | $193K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17,981 | $190K |
| 93304 | <1% | 1,320 | $185K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,624 | $175K |
| 73630 | <1% | 3,458 | $168K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,254 | $167K |
| 81025 | <1% | 28,464 | $167K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,254 | $162K |
| 73562 | <1% | 4,224 | $162K | |
| 84484 | <1% | 17,857 | $161K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,158 | $155K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,072 | $155K |
| 42830 | <1% | 111 | $147K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 7,230 | $145K |
| 80305 | <1% | 4,420 | $142K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,061 | $142K |
| 95714 | <1% | 496 | $141K | |
| 95811 | <1% | 413 | $141K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,686 | $137K |
| 94060 | <1% | 1,858 | $134K | |
| 76775 | <1% | 2,544 | $134K | |
| 73130 | <1% | 3,595 | $134K | |
| 73610 | <1% | 2,960 | $133K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,216 | $133K |
| 76536 | <1% | 2,125 | $132K | |
| 84112 | <1% | 1,692 | $132K | |
| 76770 | <1% | 1,531 | $130K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,719 | $127K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 32,080 | $126K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,950 | $125K |
| 84702 | <1% | 6,136 | $124K | |
| 71045 | Radiologic examination, chest; single view | <1% | 23,582 | $123K |
| 93975 | <1% | 3,366 | $122K | |
| 96523 | <1% | 2,017 | $121K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 6,189 | $121K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,089 | $116K |
| 96376 | <1% | 10,591 | $114K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,205 | $111K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,692 | $110K |
| 97164 | <1% | 820 | $107K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,296 | $106K |
| 87081 | <1% | 13,586 | $104K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 628 | $103K |
| 76642 | <1% | 1,951 | $103K | |
| 71250 | <1% | 2,601 | $103K | |
| 93308 | <1% | 1,083 | $102K | |
| 96415 | <1% | 2,092 | $100K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 913 | $100K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,196 | $100K |
| 73110 | <1% | 2,533 | $98K | |
| 95886 | <1% | 1,271 | $93K | |
| 73030 | <1% | 3,472 | $92K | |
| 36430 | <1% | 1,677 | $92K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 544 | $91K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,961 | $87K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,641 | $86K |
| 94618 | <1% | 2,012 | $84K | |
| 92588 | <1% | 1,566 | $84K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,364 | $84K |
| 93017 | <1% | 3,034 | $77K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 182 | $76K |
| 97168 | <1% | 940 | $75K | |
| 73140 | <1% | 1,365 | $74K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 459 | $74K |
| 74183 | <1% | 454 | $72K | |
| 85027 | <1% | 25,855 | $72K | |
| 72141 | <1% | 1,044 | $71K | |
| 73080 | <1% | 1,444 | $71K | |
| 96368 | <1% | 1,488 | $71K | |
| 70491 | <1% | 488 | $69K | |
| 72110 | <1% | 1,441 | $66K | |
| 85610 | <1% | 21,879 | $64K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,454 | $64K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 13,644 | $63K |
| 77072 | <1% | 1,561 | $63K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 27,276 | $62K |
| 92610 | <1% | 627 | $61K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 513 | $60K |
| 86140 | <1% | 10,154 | $59K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 951 | $59K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 4,448 | $55K |
| 77066 | Tomosynthesis, mammo | <1% | 1,318 | $55K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 451 | $55K |
| 94664 | <1% | 2,028 | $55K | |
| 93971 | <1% | 1,940 | $54K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 346 | $53K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,210 | $52K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 696 | $51K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 234 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,396 | $49K |
| 83880 | <1% | 4,491 | $49K | |
| 72100 | <1% | 1,346 | $48K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,995 | $48K |
| 74240 | <1% | 581 | $44K | |
| 82550 | <1% | 5,079 | $43K | |
| 77080 | <1% | 1,323 | $43K | |
| 96367 | <1% | 2,001 | $43K | |
| 73565 | <1% | 1,299 | $42K | |
| 72131 | <1% | 1,374 | $42K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,361 | $41K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 934 | $40K |
| 95951 | <1% | 275 | $40K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,222 | $40K |
| 87070 | <1% | 2,711 | $40K | |
| 73221 | <1% | 465 | $39K | |
| 76870 | <1% | 1,071 | $39K | |
| 97116 | <1% | 1,583 | $39K | |
| 97010 | <1% | 2,828 | $38K | |
| 86900 | <1% | 9,513 | $38K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 535 | $37K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,604 | $37K |
| 87428 | <1% | 3,847 | $36K | |
| 92585 | <1% | 280 | $36K | |
| 82565 | <1% | 2,430 | $36K | |
| 80320 | <1% | 5,180 | $35K | |
| 36591 | <1% | 724 | $35K | |
| 70486 | <1% | 1,044 | $35K | |
| 12011 | <1% | 1,333 | $34K | |
| 93970 | <1% | 1,047 | $34K | |
| 81229 | <1% | 70 | $34K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 6,668 | $33K |
| 73090 | <1% | 1,097 | $33K | |
| 96450 | <1% | 294 | $33K | |
| 73590 | <1% | 1,160 | $32K | |
| 74022 | <1% | 799 | $32K | |
| J1815 | Injection, insulin, per 5 units | <1% | 5,293 | $32K |
| 71271 | <1% | 646 | $32K | |
| 92582 | <1% | 421 | $31K | |
| 93226 | <1% | 822 | $31K | |
| 12001 | <1% | 976 | $31K | |
| 83735 | <1% | 12,885 | $29K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 6,538 | $28K |
| 85730 | <1% | 8,498 | $28K | |
| 94644 | <1% | 1,533 | $27K | |
| 97163 | <1% | 315 | $27K | |
| 95910 | <1% | 313 | $27K | |
| 95819 | <1% | 182 | $26K | |
| 76882 | <1% | 717 | $26K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,095 | $25K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,184 | $24K |
| 73502 | <1% | 1,628 | $23K | |
| 95911 | <1% | 302 | $23K | |
| 74019 | <1% | 1,683 | $23K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,862 | $23K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,090 | $23K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,463 | $23K |
| 76801 | <1% | 2,283 | $21K | |
| 59050 | <1% | 1,998 | $21K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,720 | $21K |
| 99201 | <1% | 280 | $20K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,695 | $20K |
| 83690 | <1% | 15,958 | $19K | |
| 80061 | Lipid panel | <1% | 4,860 | $19K |
| 96409 | <1% | 1,316 | $19K | |
| 87077 | <1% | 9,468 | $19K | |
| 92567 | <1% | 3,033 | $18K | |
| 92587 | <1% | 2,991 | $18K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 1,157 | $18K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,184 | $18K |
| 96417 | <1% | 564 | $18K | |
| 99157 | <1% | 2,215 | $17K | |
| 86901 | <1% | 9,666 | $17K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 622 | $17K |
| 87899 | <1% | 1,552 | $17K | |
| 87186 | <1% | 7,916 | $16K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 334 | $15K |
| 72040 | <1% | 709 | $15K | |
| 72158 | <1% | 260 | $15K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 401 | $15K |
| 92522 | <1% | 117 | $14K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 78 | $14K |
| 82728 | <1% | 3,155 | $14K | |
| 64493 | <1% | 134 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,946 | $14K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 706 | $14K |
| 87046 | <1% | 1,310 | $13K | |
| 73620 | <1% | 214 | $13K | |
| 92550 | <1% | 5,628 | $13K | |
| 88304 | <1% | 1,900 | $13K | |
| 94729 | <1% | 1,208 | $12K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,073 | $12K |
| J2704 | Injection, propofol, 10 mg | <1% | 16,501 | $12K |
| 82247 | <1% | 707 | $12K | |
| 86902 | <1% | 115 | $12K | |
| 84100 | <1% | 3,791 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,982 | $11K |
| 87205 | <1% | 2,818 | $11K | |
| 72156 | <1% | 83 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,365 | $11K |
| 75574 | <1% | 62 | $11K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 163 | $11K |
| 0100U | <1% | 243 | $11K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,494 | $11K |
| 84439 | <1% | 3,858 | $11K | |
| 10061 | <1% | 216 | $11K | |
| 99152 | <1% | 1,800 | $11K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,308 | $11K |
| 82805 | <1% | 800 | $10K | |
| 94760 | <1% | 3,589 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,864 | $10K |
| 84703 | <1% | 5,557 | $10K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,114 | $10K |
| 87040 | <1% | 6,108 | $9K | |
| 64721 | <1% | 14 | $9K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 14,502 | $9K |
| 92652 | <1% | 168 | $9K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 982 | $9K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 556 | $9K |
| 73070 | <1% | 88 | $9K | |
| 84156 | <1% | 1,151 | $9K | |
| 72050 | <1% | 310 | $9K | |
| 88307 | <1% | 859 | $8K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 515 | $8K |
| 83615 | <1% | 2,731 | $8K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,180 | $8K |
| 93880 | <1% | 428 | $8K | |
| 90715 | <1% | 967 | $8K | |
| 72197 | <1% | 91 | $8K | |
| 72072 | <1% | 554 | $8K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,255 | $8K |
| 93296 | <1% | 794 | $7K | |
| 85652 | <1% | 6,381 | $7K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 537 | $7K |
| 99499 | <1% | 56 | $7K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 1,037 | $7K |
| 84550 | <1% | 2,535 | $7K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,046 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,153 | $7K |
| 87116 | <1% | 684 | $7K | |
| 73560 | <1% | 1,528 | $7K | |
| 83605 | <1% | 3,810 | $7K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 172 | $7K |
| 49083 | <1% | 20 | $7K | |
| 62323 | <1% | 161 | $7K | |
| 64635 | <1% | 16 | $7K | |
| 85007 | <1% | 8,682 | $7K | |
| 96411 | <1% | 198 | $7K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 873 | $6K |
| 82607 | <1% | 1,630 | $6K | |
| 97597 | <1% | 64 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,377 | $6K |
| 96401 | <1% | 91 | $6K | |
| 82731 | <1% | 82 | $6K | |
| 74241 | <1% | 89 | $6K | |
| 94762 | <1% | 1,058 | $6K | |
| 12002 | <1% | 295 | $6K | |
| 19083 | <1% | 26 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 284 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 841 | $6K |
| C1769 | Guide wire | <1% | 619 | $6K |
| 73552 | <1% | 311 | $6K | |
| 87015 | <1% | 686 | $5K | |
| 85379 | <1% | 3,308 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,276 | $5K |
| 27096 | <1% | 27 | $5K | |
| 87206 | <1% | 685 | $5K | |
| 73660 | <1% | 113 | $5K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 305 | $5K |
| 82784 | <1% | 1,838 | $5K | |
| 72146 | <1% | 79 | $5K | |
| 86923 | <1% | 1,210 | $5K | |
| 87486 | <1% | 3,257 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,786 | $5K |
| 97167 | <1% | 91 | $5K | |
| 87102 | <1% | 667 | $5K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 129 | $5K |
| 87581 | <1% | 3,253 | $5K | |
| 64483 | <1% | 87 | $5K | |
| 87425 | <1% | 482 | $5K | |
| 87075 | <1% | 493 | $5K | |
| 92521 | <1% | 31 | $5K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 497 | $5K |
| 83550 | <1% | 2,330 | $4K | |
| 83540 | <1% | 2,584 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,841 | $4K |
| 80197 | <1% | 386 | $4K | |
| 29125 | <1% | 1,360 | $4K | |
| 88108 | <1% | 831 | $4K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 866 | $4K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 700 | $4K |
| 83970 | <1% | 276 | $4K | |
| 70480 | <1% | 46 | $4K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 156 | $4K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 356 | $4K |
| 29530 | <1% | 475 | $4K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,385 | $4K |
| 87210 | <1% | 1,806 | $4K | |
| 73060 | <1% | 169 | $4K | |
| 88312 | <1% | 2,631 | $3K | |
| 82248 | <1% | 4,680 | $3K | |
| 89050 | <1% | 506 | $3K | |
| 36592 | <1% | 246 | $3K | |
| 80074 | <1% | 322 | $3K | |
| 73000 | <1% | 111 | $3K | |
| 72157 | <1% | 14 | $3K | |
| 93321 | <1% | 2,826 | $3K | |
| 10060 | <1% | 95 | $3K | |
| 87653 | <1% | 230 | $3K | |
| 29515 | <1% | 1,114 | $3K | |
| 96160 | <1% | 297 | $3K | |
| 58661 | <1% | 14 | $3K | |
| 97035 | <1% | 274 | $3K | |
| 73523 | <1% | 141 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,802 | $3K |
| 00731 | <1% | 2,286 | $3K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24 | $3K |
| 95912 | <1% | 41 | $3K | |
| 85384 | <1% | 1,817 | $3K | |
| 20553 | <1% | 45 | $2K | |
| 70360 | <1% | 138 | $2K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 76 | $2K |
| 72170 | <1% | 451 | $2K | |
| 74174 | <1% | 13 | $2K | |
| 71101 | <1% | 57 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 649 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 367 | $2K |
| 83516 | <1% | 622 | $2K | |
| 80164 | <1% | 555 | $2K | |
| 87045 | <1% | 1,277 | $2K | |
| 73564 | <1% | 81 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 205 | $2K |
| 88302 | <1% | 158 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,303 | $2K |
| 92551 | <1% | 97 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,477 | $2K |
| 80329 | <1% | 2,039 | $2K | |
| 76857 | <1% | 297 | $2K | |
| 94660 | <1% | 84 | $2K | |
| 85045 | <1% | 5,243 | $2K | |
| 29105 | <1% | 589 | $2K | |
| 29540 | <1% | 301 | $2K | |
| 64450 | <1% | 40 | $2K | |
| 93225 | <1% | 834 | $2K | |
| 73100 | <1% | 131 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,060 | $2K |
| 20610 | <1% | 79 | $2K | |
| 84481 | <1% | 176 | $2K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 67 | $2K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 1,110 | $2K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,236 | $2K |
| 82533 | <1% | 226 | $2K | |
| 74181 | <1% | 15 | $2K | |
| 88313 | <1% | 1,387 | $2K | |
| 72128 | <1% | 356 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 47 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,183 | $1K |
| 51701 | <1% | 3,176 | $1K | |
| 87340 | <1% | 470 | $1K | |
| 86803 | <1% | 454 | $1K | |
| 82043 | <1% | 302 | $1K | |
| 86592 | <1% | 838 | $1K | |
| 86003 | <1% | 315 | $1K | |
| 00400 | <1% | 865 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 857 | $1K |
| 87147 | <1% | 579 | $1K | |
| 86364 | <1% | 309 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 944 | $1K |
| 74230 | <1% | 13 | $1K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 358 | $1K |
| 82553 | <1% | 105 | $1K | |
| 89055 | <1% | 243 | $1K | |
| 99156 | <1% | 1,472 | $1K | |
| 93356 | <1% | 320 | $1K | |
| 94727 | <1% | 1,148 | $1K | |
| 94010 | <1% | 43 | $1K | |
| 76886 | <1% | 12 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 913 | $1K |
| 00813 | <1% | 1,492 | $1K | |
| 84134 | <1% | 282 | $1K | |
| 82746 | <1% | 724 | $1K | |
| 82785 | <1% | 590 | $1K | |
| 82150 | <1% | 1,902 | $978.10 | |
| 87507 | <1% | 158 | $938.06 | |
| A0425 | Ground mileage, per statute mile | <1% | 381 | $919.45 |
| 82330 | <1% | 645 | $918.79 | |
| 83020 | <1% | 392 | $851.39 | |
| 92555 | <1% | 578 | $805.50 | |
| 64447 | <1% | 153 | $798.25 | |
| 88341 | <1% | 79 | $774.89 | |
| 86665 | <1% | 81 | $765.31 | |
| 74270 | <1% | 14 | $748.26 | |
| 94761 | <1% | 60 | $737.10 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 120 | $735.93 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 25 | $733.06 |
| 74220 | <1% | 25 | $729.87 | |
| 90686 | <1% | 651 | $722.86 | |
| 83002 | <1% | 221 | $706.84 | |
| 64415 | <1% | 71 | $697.07 | |
| 99155 | <1% | 1,392 | $680.08 | |
| 86870 | <1% | 64 | $614.82 | |
| 95700 | <1% | 526 | $587.71 | |
| 01830 | <1% | 143 | $581.20 | |
| 01480 | <1% | 13 | $550.17 | |
| 62322 | <1% | 13 | $549.41 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 151 | $533.30 |
| 77001 | <1% | 43 | $523.27 | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $490.52 |
| 29130 | <1% | 135 | $488.40 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 134 | $476.41 |
| A4590 | Special casting material (e.g., fiberglass) | <1% | 105 | $458.71 |
| 77002 | <1% | 111 | $455.22 | |
| 82105 | <1% | 83 | $445.70 | |
| 00840 | <1% | 1,289 | $439.16 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 401 | $427.23 |
| 24640 | <1% | 19 | $424.17 | |
| 51798 | <1% | 27 | $394.22 | |
| 00790 | <1% | 283 | $362.32 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 15 | $358.80 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $358.80 |
| 82274 | <1% | 12 | $350.34 | |
| 86922 | <1% | 87 | $345.28 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,321 | $327.88 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 1,083 | $312.32 |
| 83993 | <1% | 13 | $286.76 | |
| 82010 | <1% | 390 | $264.04 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 71 | $234.78 |
| 86308 | <1% | 514 | $233.86 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 482 | $223.58 |
| 92653 | <1% | 12 | $208.28 | |
| 74178 | <1% | 30 | $196.24 | |
| 84145 | <1% | 734 | $191.64 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 2,143 | $190.57 |
| J1335 | Injection, ertapenem sodium, 500 mg | <1% | 61 | $189.61 |
| 83655 | <1% | 66 | $187.15 | |
| 85018 | <1% | 128 | $183.73 | |
| 0650T | <1% | 29 | $182.00 | |
| 84157 | <1% | 45 | $173.24 | |
| 69210 | <1% | 12 | $170.22 | |
| 72220 | <1% | 13 | $164.23 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 47 | $160.72 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 379 | $155.96 |
| 00300 | <1% | 484 | $154.60 | |
| C1776 | Joint device (implantable) | <1% | 479 | $150.00 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 414 | $142.39 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 670 | $142.21 |
| 00811 | <1% | 615 | $141.50 | |
| 95885 | <1% | 142 | $132.00 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 14 | $116.60 |
| 84305 | <1% | 527 | $116.20 | |
| 93280 | <1% | 16 | $114.24 | |
| 87076 | <1% | 17 | $112.36 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 210 | $112.22 |
| 86376 | <1% | 399 | $112.13 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 356 | $102.32 |
| 86038 | <1% | 276 | $99.95 | |
| V5299 | Hearing service, miscellaneous | <1% | 81 | $89.32 |
| 82977 | <1% | 680 | $86.32 | |
| 83021 | <1% | 42 | $77.36 | |
| 84132 | <1% | 283 | $68.77 | |
| 76827 | <1% | 12 | $68.54 | |
| 86800 | <1% | 87 | $67.19 | |
| 83520 | <1% | 48 | $63.95 | |
| 88342 | <1% | 286 | $63.47 | |
| 86304 | <1% | 16 | $62.01 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 3,389 | $59.11 |
| 82945 | <1% | 28 | $56.45 | |
| 85014 | <1% | 56 | $48.35 | |
| 82575 | <1% | 26 | $45.07 | |
| 88331 | <1% | 19 | $42.12 | |
| 86360 | <1% | 27 | $42.07 | |
| 84403 | <1% | 362 | $39.97 | |
| 83525 | <1% | 217 | $39.62 | |
| 87634 | <1% | 14 | $35.00 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 406 | $34.01 |
| 86359 | <1% | 27 | $31.56 | |
| 86762 | <1% | 30 | $28.47 | |
| 80076 | <1% | 15 | $27.27 | |
| 81243 | <1% | 14 | $27.21 | |
| 84402 | <1% | 121 | $25.01 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 19 | $24.64 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 87 | $22.50 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 64 | $22.09 |
| 87799 | <1% | 19 | $21.02 | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 524 | $17.64 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 146 | $16.80 |
| 87806 | <1% | 12 | $16.67 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 44 | $14.18 |
| 64494 | <1% | 137 | $13.00 | |
| 83001 | <1% | 165 | $12.92 | |
| 00126 | <1% | 734 | $12.91 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 14 | $11.04 |
| 76942 | <1% | 19 | $8.06 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $7.39 |
| 82140 | <1% | 33 | $6.68 | |
| 84311 | <1% | 145 | $6.16 | |
| 01810 | <1% | 151 | $6.16 | |
| 64495 | <1% | 40 | $5.32 | |
| 87329 | <1% | 16 | $2.32 | |
| 87328 | <1% | 16 | $2.32 | |
| G0008 | Administration of influenza virus vaccine | 0% | 115 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 136 | $0.00 |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 0% | 16 | $0.00 |
| 90656 | 0% | 257 | $0.00 | |
| 86664 | 0% | 97 | $0.00 | |
| 90677 | 0% | 136 | $0.00 | |
| 88184 | 0% | 16 | $0.00 | |
| 01400 | 0% | 73 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 40 | $0.00 |
| 90697 | 0% | 31 | $0.00 | |
| 87449 | 0% | 13 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 15 | $0.00 |
| 86403 | 0% | 14 | $0.00 | |
| 00160 | 0% | 38 | $0.00 | |
| 76377 | 0% | 13 | $0.00 | |
| 88311 | 0% | 30 | $0.00 | |
| 90680 | 0% | 45 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 13 | $0.00 |
| 86141 | 0% | 16 | $0.00 | |
| 00920 | 0% | 605 | $0.00 | |
| J1105 | Dexmedetomidine, oral, 1 mcg | 0% | 40 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 12 | $0.00 |
| 94645 | 0% | 33 | $0.00 | |
| C1876 | Stent, non-coated/non-covered, with delivery system | 0% | 83 | $0.00 |
| 29505 | 0% | 27 | $0.00 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 13 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 22 | $0.00 |
| 64636 | 0% | 16 | $0.00 | |
| 92611 | 0% | 13 | $0.00 | |
| 82272 | 0% | 12 | $0.00 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 16 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 57 | $0.00 |
| 82570 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPENCE, BENJAMIN (CHEIF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Lee Memorial Health System | Fort Myers, FL | $15.11M |
| Cape Memorial Hospital INC | Cape Coral, FL | $13.77M |
| Lee Memorial Health System | Fort Myers, FL | $11.06M |
| Lee Memorial Health System | Fort Myers, FL | $1.60M |
| Lee Memorial Health System | Lehigh Acres, FL | $1.25M |
| Lee Memorial Health System | Fort Myers, FL | $928K |
| Access Medical South, LC | Fort Myers, FL | $856K |
| Lee Memorial Health System | Lehigh Acres, FL | $506K |
| Lee Memorial Health System | Fort Myers, FL | $333K |
| Lee Memorial Health System | North Fort Myers, FL | $192K |
| Lee Memorial Health System | Cape Coral, FL | $177K |
| Lee Memorial Health System | Fort Myers, FL | $171K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.